|
|
№3 (приложение) / 2023
|
|
|
№3 (приложение) / 2023
|
|
Kislyak O.A., Mikaelyan A.A., Starodubova A.V., Kosyura S.D.
Cardiovascular and metabolic risks in patients with obesity and non-alcoholic fatty liver disease
|
№3 / 2023
|
|
Shulkina S.G., Erbes P.E., Smirnov E.N.
The contribution of the polymorphism of MMR 12 (rs652483) and PPARG (rs1801282) genes to the formation of NAFLD in obese patients
|
№10 / 2022
|
|
Prikhodko V.A., Okovity S.V.
Neuropsychiatric disorders of non-alcoholic fatty liver disease
|
№7 / 2022
|
|
Tarzimanova A.I.
The significance of non-alcoholic fatty liver disease in atrial fibrillation development: view of cardiologist
|
№5 / 2022
|
|
Yagoda A.V., Geyvandova T.V., Rogova S.Sh., Geyvandova N.I.
The clinical significance of blood leptin in patients with non-alcoholic fatty liver disease associated with obesity
|
№3 / 2019
|
|
Koroy P.V., Slyadnev S.A., Kravchenko Yu.A., Yagoda A.V.
Influence of metabolic syndrome on course of non-alcoholic fatty liver disease
|
№3 / 2019
|
|
E.V. Golovanova
Ammonia as an actual problem of a doctor and patient in therapeutic practice
|
№2 / 2018
|
|
M.Ye. Statsenko, S.V. Turkina, N.N. Shilina, M.A. Kosivtsova
Potentials for the additional medical correction using cytoprotectors in patients with chronic heart failure and nonalcoholic fatty liver disease
|
№1 / 2017
|
Русский
